ACLARUSDX
LIVE

Serial Number

79079325

Owner

EXONHIT S.A.

Filing Date

Nov 24, 2009

Add to watchlist:

No watchlists yet
View on USPTO

ACLARUSDX Trademark

Serial Number: 79079325 • Registration: 4021169

ACLARUSDX is a trademark filed by EXONHIT S.A. on November 24, 2009. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

EXONHIT S.A. (5 trademarks)

63-65 BOULEVARD MASSENA
PARIS 75013 , FR

Entity Type: 11

ExonHit Therapeutics (3 trademarks)

26, rue Brunel

Entity Type: 99

Trademark Details

Filing Date

November 24, 2009

Registration Date

September 6, 2011

Published for Opposition

June 21, 2011

Cancellation Date

November 24, 2019

Goods & Services

Pharmaceutical preparations for treating neurodegenerative diseases and particularly Alzheimer's disease; tests, namely, a blood based biomarker test to identify patients with Alzheimer's disease or at risk of developing the disease and identifying patients responding to specific treatments; biological products and preparations acids for pharmaceutical use, namely, pharmaceutical preparations for the diagnostic of the Alzheimer's disease; capsules sold empty for medicines and diagnostic tests; chemical-pharmaceutical preparations for the diagnosis, the prevention or the treatment of Alzheimer's disease; biopharmaceutical preparations for the diagnosis, the prevention or the treatment of Alzheimer's disease; chemical preparations for medical, pharmaceutical or veterinary use, namely, for diagnosing neurodegenerative diseases and particularly Alzheimer's disease; medical and clinical diagnostic products, namely, probe sets, namely, subset of nucleic acid sequences and nucleic acid libraries, namely, DNA libraries and RNA libraries; nucleic acid sequences for use on biochips, namely, for decoding genes affected by the Alzheimer's disease or revealing the transcriptomic signature of patients affected with Alzheimer's disease; enzymes or enzyme preparations for medical or veterinary use, namely, enzymes stabilizers, namely, enzymes for medical purposes or veterinary use, namely, for treatment of Alzheimer's disease, enzyme substrates, namely, enzymes for medical purposes or veterinary use, namely, for treatment of Alzheimer's disease used as an ingredient in drugs against Alzheimer's disease

Chemicals and chemical compositions, namely, nucleic acids attached to a solid support for use in industry and science; analyses, namely, reagent for chemical analyses, namely, quantification of nucleic acid content in laboratories chemical preparations for analyses, other than for medical or veterinary use; biological preparations, namely, quantification of nucleic acid content other than for medical or veterinary use, namely, inoculants, namely, biological microorganisms used in fermentation of silage; chemical preparations for scientific use, other than for medical or veterinary use; chemical preparations or reagents for laboratory, other than for medical or veterinary use; chemical preparations for scientific use, namely, nucleic acid libraries to screen and analyze gene expression, to identify therapeutic targets and products, and to conduct pharmacogenomic and genotoxicity research in the fields of pharmacology, food, chemistry, cosmetology, plant protection, and veterinary sciences; chemical preparations for scientific use, namely, DNA biochips for decoding genes affected by the Alzheimer's disease or revealing the transcriptomic signature of patients affected with Alzheimer's disease, and DNA chips to make visible and analyze gene expression in the fields of human and pharmacological medicine and veterinary science

Medical services; veterinary services; medical assistance services; providing medical information, consultancy and advisory services; hospital services; pharmacists' services relating to the pharmaceutical industry, namely, the filling of and making up prescriptions; health care; telemedicine services

Surgical, medical, dental and veterinary apparatus and instruments, namely, for disease identification, measure of disease severity, measure of disease prognosis, measure of disease progression, measure of disease conversion; medical devices, namely, biochips for analysis of blood; blood testing apparatus; devices, namely, biochips for medical diagnostics uses, namely, biochips for diagnosing Alzheimer's disease, namely, collection kit for blood sampling to perform the test in the right conditions; spoons for administering medicine; receptacles for applying medicines; ultrasound probes for medical use; syringes for medical use; galvanic therapeutic medical devices to diagnose neurodegenerative diseases and particularly Alzheimer's disease

Research and development for third parties in relation to pharmaceutical molecules or biological markers, medicines for the diagnosis and treatment of neurodegenerative diseases; chemical analysis; chemical research; chemical services, namely, analysis of RNA, genes, tissue and blood sample; biotechnology project studies, namely, identifying population of patients affected by the Alzheimer disease and measuring the disease's severity, prognosis, progression and conversion and determining patients sensitivity to treatment; research and development of new products for third parties; biological research; research in biotechnology; technical research in the field of biotechnology; biotechnology analysis services

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Dec 12, 2020 DENC
DEATH OF INTERNATIONAL REGISTRATION
Dec 12, 2020 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Sep 25, 2015 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 2, 2015 INTS
INVALIDATION PROCESSED
Sep 2, 2015 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Aug 5, 2015 INTR
CANCELLED SECTION 7-TOTAL
Dec 5, 2014 C7..
CANCELLATION TERMINATED NO. 999999
Dec 5, 2014 CANT
CANCELLATION DENIED NO. 999999
Dec 3, 2014 CAND
CANCELLATION INSTITUTED NO. 999999
Oct 24, 2014 PETC
FINAL DECISION TRANSACTION PROCESSED BY IB
May 19, 2013 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 8, 2012 FICS
FINAL DISPOSITION PROCESSED
Mar 8, 2012 FIMP
NOTIFICATION PROCESSED BY IB
Dec 18, 2011 GPNX
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 6, 2011 FICR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Oct 15, 2011 ADCH
REGISTERED-PRINCIPAL REGISTER
Sep 6, 2011 R.PR
NOTIFICATION PROCESSED BY IB
Sep 3, 2011 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 17, 2011 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Aug 17, 2011 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 21, 2011 NPUB
PUBLISHED FOR OPPOSITION
Jun 21, 2011 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 1, 2011 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 1, 2011 OP2R
LAW OFFICE PUBLICATION REVIEW COMPLETED
May 19, 2011 PREV
ASSIGNED TO LIE
May 19, 2011 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
May 6, 2011 CNSA
ASSIGNED TO EXAMINER
Mar 8, 2011 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 8, 2011 TCCA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 8, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 8, 2011 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 8, 2011 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 9, 2010 GNFN
FINAL REFUSAL E-MAILED
Aug 9, 2010 GNFR
FINAL REFUSAL WRITTEN
Aug 9, 2010 CNFR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 12, 2010 TCCA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 12, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 12, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 12, 2010 TROA
REFUSAL PROCESSED BY IB
Apr 30, 2010 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 19, 2010 RFCS
REFUSAL PROCESSED BY MPU
Mar 19, 2010 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 19, 2010 RFCR
APPLICATION FILING RECEIPT MAILED
Mar 19, 2010 MAFR
NON-FINAL ACTION WRITTEN
Mar 18, 2010 CNRT
ASSIGNED TO EXAMINER
Mar 15, 2010 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 15, 2010 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 11, 2010 REPR